Baird Initiates Coverage On Agilon Health with Neutral Rating, Announces Price Target of $6
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Michael Halloran has initiated coverage on Agilon Health (NYSE:AGL) with a Neutral rating and set a price target of $6.
May 30, 2024 | 9:37 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Baird analyst Michael Halloran has initiated coverage on Agilon Health with a Neutral rating and set a price target of $6.
The Neutral rating suggests that the analyst does not expect significant short-term movement in the stock price. The price target of $6 provides a specific valuation benchmark for investors.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100